Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SVF + PRP versus conservative management for focal chondral lesions of the knee
ACTRN12616001259437Phase 2Withdrawn
- Sponsor
- Cell-Innovations
- Start
- Feb 2024
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous adipose-derived stromal vascular fraction and platelet-rich plasma in chondral knee defect (2 arms), sponsored by Cell-Innovations. Primary endpoint: Safety and tolerability of autologous stromal vascular fraction and platelet-rich plasma. Planned start Feb 2024; status: withdrawn.
02
Drugs
autologous adipose-derived stromal vascular fractionplatelet-rich plasma
03
Conditions
chondral knee defect
Beyond the preview
Go deeper on ACTRN12616001259437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001259437.